Minoryx Therapeutics Appoints Chair
This article was originally published in Scrip
Minoryx Therapeutics, a company focused on orphan diseases, has appointed Dr. Khalid Islam chair of the company's board of directors. Islam has 27 years' experience in the pharma and biotech industry and was previously chair and CEO of Gentium S.p.a and previously he was president and CEO of Arpida AG. Prior to this, he worked in academia at Imperial College (University of London) and at Milan University, where he was a contract professor.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.